ClinicalTrials.gg
CompletedNCT04613518Updated Jul 12, 2024Results posted

A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis

A Phase 2 interventional study of BMS-986165 and Placebo Comparator in Colitis, Ulcerative, sponsored by Bristol-Myers Squibb. Completed at 26 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-07-12.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Colitis, Ulcerative by Bristol-Myers Squibb — 4 open to participants now, 5 under way, 1 of them phase 3. Colitis, Ulcerative · Bristol-Myers Squibb.

Enrollment
15th of 17
38 · median 131
Started
2021
with 1 other
Phase 2
7 of 22
none open now
Registered
13th of 22
by date

Among the 22 studies in Colitis, Ulcerative by Bristol-Myers Squibb, this one is the 15th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2021, is one of 7 in phase 2, and was the 13th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

4 of the 22 studies in Colitis, Ulcerative by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Colitis, Ulcerative by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and tolerability, efficacy, and biomarker response of BMS-986165 administered orally in participants with moderate to severe ulcerative colitis. The study was originally designed to test deucravacitinib at two doses for 12 weeks compared to placebo. After the initial 12-Week period, all subjects receive active therapy (open-label extension). With protocol amendment 2, one of the dose treatment arms is being removed from the 12-week double blind period with no change to the open-label extension.

03

Conditions studied

  • Colitis, Ulcerative

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of ulcerative colitis (UC) at least 3 months' duration prior to screening
  • Moderately to severely active UC as assessed by the modified Mayo score
  • Documentation of an inadequate response, loss of response, or intolerance to a treatment course of 1 or more of the following standard of care medications: oral 5-aminosalicylic acids, , immunomodulators, anti-tumor necrosis factor (TNF) agents, integrin inhibitors[SA1]
  • Documentation of prior treatment with corticosteroids for ≥ 4 weeks
  • Males and females must agree to follow specific methods of , if applicable

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of Crohn's disease (CD) or diagnosis of indeterminate colitis (IC), ischemic colitis, or pseudomembranous colitis
  • Current evidence of fulminant colitis, abdominal abscess, toxic megacolon, or bowel perforation
  • History or evidence of any extensive colonic resection, or subtotal or total colectomy
  • Women who are pregnant or breastfeeding
  • Prior exposure to BMS-986165 or a tyrosine kinase 2 (TYK2) inhibitor

Other protocol-defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    BMS-986165

    Drug: BMS-986165

  • Placebo comparator
    Placebo

    Other: Placebo Comparator

  • Experimental
    Open label Extension, BMS-986165

    Drug: BMS-986165

Interventions

  • Specified Dose on Specified Days

  • OtherPlacebo Comparator

    Specified Dose on Specified Days

06

What researchers measure

Primary outcomes

  1. Percentage of Participants in Clinical Response at Week 12

    Clinical response is defined as achieving the following changes in the modified Mayo score (excludes the physicians' global assessment) * A decrease from baseline in the modified Mayo score of ≥ 2 points, and * A decrease from baseline in the modified Mayo score ≥ 30%, and * A decrease in rectal bleeding (RB) subscore of ≥ 1 point or absolute RB subscore ≤ 1 Note: The modified Mayo score calculated to determine eligibility will also be used as the baseline disease activity score. The modified Mayo score is a 9-point scale (a score of 5 to 9 points denotes moderate to severe disease). The modified Mayo score is a sum of the following 3 components: * Stool frequency (SF) subscore (0 to 3) * Rectal bleeding (RB) subscore (0 to 3) * Endoscopic (ES) subscore (0 to 3)

    Time frame: At week 12

  2. Number of Participants Experiencing Adverse Events (AEs)

    An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Note: the first dose of study treatment in the open-label period may be the same as the last dose date of study treatment in double-blind treatment period, therefore, the participants analyzed in the open-label period may contain double blind participants finishing their last dose in the double-blind treatment period.

    Time frame: From first dose up to the last dose in the double-blind period or 30 days post the last dose date if not treated in the open-label period and from the first dose in open-label period up to 30 days post the last dose date (up to approximately 402 days)

  3. Number of Participants Experiencing Serious Adverse Events (SAEs)

    An SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability or permanent damage, is a congenital anomaly/birth defect, is an important medical event. Note: the first dose of study treatment in the open-label period may be the same as the last dose date of study treatment in double-blind treatment period, therefore, the participants analyzed in the open-label period may contain double blind participants finishing their last dose in the double-blind treatment period.

    Time frame: From first dose up to the last dose in the double-blind period or 30 days post the last dose date if not treated in the open-label period and from the first dose in open-label period up to 30 days post the last dose date (up to approximately 402 days)

  4. Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation

    An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Note: the first dose of study treatment in the open-label period may be the same as the last dose date of study treatment in double-blind treatment period, therefore, the participants analyzed in the open-label period may contain double blind participants finishing their last dose in the double-blind treatment period.

    Time frame: From first dose up to the last dose in the double-blind period or 30 days post the last dose date if not treated in the open-label period and from the first dose in open-label period up to 30 days post the last dose date (up to approximately 402 days)

  5. Number of Participants Experiencing Adverse Events of Special Interest (AEIs)

    An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. AEs of special interest include: skin events, influenza, herpes viral infections, opportunistic infections, tuberculosis, cardiovascular events, malignancy, and COVID-19.

    Time frame: From first dose to 52 weeks after first dose

07

Results

Posted Jul 12, 2024

Participant flow

Double-Blind Treatment Period
Participant flow — Double-Blind Treatment Period
MilestoneBMS-986165 12 mg BIDBMS-986165 6 mg BIDPlacebo BID PO
Started2648
Completed1937
Not completed711
Withdrew: Lack of efficacy100
Withdrew: Adverse event201
Withdrew: Participant request to discontinue treatment100
Withdrew: Participant withdrew consent110
Withdrew: Other reasons200
Open-Label Treatment Period
Participant flow — Open-Label Treatment Period
MilestoneBMS-986165 12 mg BIDBMS-986165 6 mg BIDPlacebo BID PO
Started1937
Completed1101
Not completed836
Withdrew: Lack of efficacy030
Withdrew: Adverse event103
Withdrew: Participant request to discontinue treatment100
Withdrew: Participant withdrew consent103
Withdrew: Administrative reason by sponsor400
Withdrew: Other reasons100

Outcome measures

PrimaryPercentage of Participants in Clinical Response at Week 12

Clinical response is defined as achieving the following changes in the modified Mayo score (excludes the physicians' global assessment) * A decrease from baseline in the modified Mayo score of ≥ 2 points, and * A decrease from baseline in the modified Mayo score ≥ 30%, and * A decrease in rectal bleeding (RB) subscore of ≥ 1 point or absolute RB subscore ≤ 1 Note: The modified Mayo score calculated to determine eligibility will also be used as the baseline disease activity score. The modified Mayo score is a 9-point scale (a score of 5 to 9 points denotes moderate to severe disease). The modified Mayo score is a sum of the following 3 components: * Stool frequency (SF) subscore (0 to 3) * Rectal bleeding (RB) subscore (0 to 3) * Endoscopic (ES) subscore (0 to 3)

Time frame:
At week 12
Reported as:
Number · Percentage of participants
Percentage of Participants in Clinical Response at Week 12
Percentage of participantsBMS-986165 12 mg BIDPlacebo BID PO
Percentage of Participants in Clinical Response at Week 1253.8 (33.4 to 73.4)50.0 (15.7 to 84.3)
Statistical analysis
  • BMS-986165 12 mg BID vs Placebo BID PO · Mean difference (final values): 3.8 · 95% CI -35.7 to 43.4
PrimaryNumber of Participants Experiencing Adverse Events (AEs)

An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Note: the first dose of study treatment in the open-label period may be the same as the last dose date of study treatment in double-blind treatment period, therefore, the participants analyzed in the open-label period may contain double blind participants finishing their last dose in the double-blind treatment period.

Time frame:
From first dose up to the last dose in the double-blind period or 30 days post the last dose date if not treated in the open-label period and from the first dose in open-label period up to 30 days post the last dose date (up to approximately 402 days)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events (AEs)
ParticipantsBMS-986165 12 mg BIDPlacebo BID PO
Double-Blind Treatment Period216
Open-Label Treatment Period156
PrimaryNumber of Participants Experiencing Serious Adverse Events (SAEs)

An SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability or permanent damage, is a congenital anomaly/birth defect, is an important medical event. Note: the first dose of study treatment in the open-label period may be the same as the last dose date of study treatment in double-blind treatment period, therefore, the participants analyzed in the open-label period may contain double blind participants finishing their last dose in the double-blind treatment period.

Time frame:
From first dose up to the last dose in the double-blind period or 30 days post the last dose date if not treated in the open-label period and from the first dose in open-label period up to 30 days post the last dose date (up to approximately 402 days)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Serious Adverse Events (SAEs)
ParticipantsBMS-986165 12 mg BIDPlacebo BID PO
Double-Blind Treatment Period41
Open-Label Treatment Period11
PrimaryNumber of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation

An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Note: the first dose of study treatment in the open-label period may be the same as the last dose date of study treatment in double-blind treatment period, therefore, the participants analyzed in the open-label period may contain double blind participants finishing their last dose in the double-blind treatment period.

Time frame:
From first dose up to the last dose in the double-blind period or 30 days post the last dose date if not treated in the open-label period and from the first dose in open-label period up to 30 days post the last dose date (up to approximately 402 days)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation
ParticipantsBMS-986165 12 mg BIDPlacebo BID PO
Double-Blind Treatment Period20
Open-Label Treatment Period13
PrimaryNumber of Participants Experiencing Adverse Events of Special Interest (AEIs)

An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. AEs of special interest include: skin events, influenza, herpes viral infections, opportunistic infections, tuberculosis, cardiovascular events, malignancy, and COVID-19.

Time frame:
From first dose to 52 weeks after first dose
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events of Special Interest (AEIs)
ParticipantsBMS-986165 12 mg BIDPlacebo BID PO
Skin Events155
Influenza12
Herpes Viral Infections00
Opportunistic Infections00
Tuberculosis00
Cardiovascular events10
Malignancy00
COVID-1930

Adverse events

Collected over All-cause mortality was assessed from first dose to study completion (up to approximately 420 days). SAEs and Other AEs were assessed from first dose to 30 days following last dose (up to approximately 402 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BMS-986165 12 mg BID (Double-Blind Treatment Period)0/26 (0%)4/26 (15.4%)19/26 (73.1%)
BMS-986165 6 mg BID (Double-Blind Treatment Period)0/4 (0%)0/4 (0%)4/4 (100%)
Placebo BID PO (Double-Blind Treatment Period)0/8 (0%)1/8 (12.5%)6/8 (75%)
BMS-986165 6 mg BID (Open-Label Treatment Period)0/29 (0%)2/29 (6.9%)20/29 (69%)
Most frequent serious events
Most frequent serious events
EventBMS-986165 12 mg BID (Double-Blind Treatment Period)BMS-986165 6 mg BID (Double-Blind Treatment Period)Placebo BID PO (Double-Blind Treatment Period)BMS-986165 6 mg BID (Open-Label Treatment Period)
Colitis ulcerativeGastrointestinal disorders2/260/41/81/29
Bacteroides bacteraemiaInfections and infestations1/260/40/80/29
NephrolithiasisRenal and urinary disorders1/260/40/80/29
Deep vein thrombosisVascular disorders1/260/40/80/29
Anal fissureGastrointestinal disorders0/260/40/81/29
Most frequent other events
Showing 10 of 31
Most frequent other events
EventBMS-986165 12 mg BID (Double-Blind Treatment Period)BMS-986165 6 mg BID (Double-Blind Treatment Period)Placebo BID PO (Double-Blind Treatment Period)BMS-986165 6 mg BID (Open-Label Treatment Period)
AcneSkin and subcutaneous tissue disorders8/263/41/85/29
NauseaGastrointestinal disorders1/261/41/80/29
Back painMusculoskeletal and connective tissue disorders0/261/40/81/29
RashSkin and subcutaneous tissue disorders4/260/40/81/29
Dry eyeEye disorders0/260/41/80/29
Abdominal painGastrointestinal disorders1/260/41/80/29
Colitis ulcerativeGastrointestinal disorders0/260/41/81/29
GastritisGastrointestinal disorders0/260/41/80/29
Gastrointestinal disorderGastrointestinal disorders0/260/41/80/29
HaemorrhoidsGastrointestinal disorders0/260/41/80/29

Baseline characteristics

Age, Continuous
Age, Continuous(Years)BMS-986165 12 mg BIDBMS-986165 6 mg BIDPlacebo BID POTotal
Mean41.8 ± 14.428.8 ± 6.738.0 ± 15.139.6 ± 14.2
Sex: Female, Male
Sex: Female, Male(Participants)BMS-986165 12 mg BIDBMS-986165 6 mg BIDPlacebo BID POTotal
Female122216
Male142622
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BMS-986165 12 mg BIDBMS-986165 6 mg BIDPlacebo BID POTotal
Hispanic or Latino0000
Not Hispanic or Latino243633
Unknown or Not Reported2125
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BMS-986165 12 mg BIDBMS-986165 6 mg BIDPlacebo BID POTotal
American Indian or Alaska Native0101
Asian1012
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White253735
More than one race0000
Unknown or Not Reported0000
08

Study locations

26 sites
  • Local Institution - 0014
    San Diego, California 92123, United States
  • Local Institution - 0036
    Arlington Heights, Illinois 60005, United States
  • Local Institution - 0016
    Shreveport, Louisiana 71105, United States
  • Local Institution - 0015
    New York, New York 10029, United States
  • Local Institution - 0026
    Chapel Hill, North Carolina 27599-7080, United States
  • Local Institution - 0013
    Cleveland, Ohio 44195, United States
  • Local Institution - 0020
    Oklahoma City, Oklahoma 73112, United States
  • Local Institution - 0032
    Garland, Texas 75044, United States
  • Local Institution - 0039
    Lubbock, Texas 74910, United States
  • Local Institution - 0033
    Southlake, Texas 76092, United States
  • Local Institution - 0005
    Sydney, New South Wales 2010, Australia
  • Local Institution - 0002
    Camberwell, Victoria 3142, Australia
  • Local Institution - 0007
    Edmonton, Alberta T6K4B2, Canada
  • Local Institution - 0025
    London, Ontario N6A 5A5, Canada
  • Local Institution - 0008
    Vaughan, Ontario L4L 4Y7, Canada
  • Local Institution - 0003
    Berlin, 12200, Germany
  • Local Institution - 0019
    Dresden, 01307, Germany
  • Local Institution - 0006
    Kiel, 24105, Germany
  • Local Institution - 0009
    Amsterdam, Noord-Holland 1081 HZ, Netherlands
  • Local Institution - 0031
    Warsaw, Mazowieckie 02-798, Poland
  • Local Institution - 0030
    Warszawa, Mazowieckie 04-501, Poland
  • Local Institution - 0029
    Bydgoszcz, 85-231, Poland
  • Local Institution - 0028
    Bydgoszcz, 85-794, Poland
  • Local Institution - 0011
    San Juan, 00935, Puerto Rico
  • Local Institution - 0023
    London, England E11 1NR, United Kingdom
  • Local Institution - 0027
    Cambridge, CB2 0QQ, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in May 2023, 26 months.

Results were first posted in Jul 2024, 1 year 1 month after primary completion.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 26 months is close to that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2020
First posted
Nov 3, 2020
StartActual
Mar 15, 2021
Primary completionActual
May 31, 2023
CompletionActual
Nov 29, 2023
Results first posted
Jul 12, 2024
Last update
Jul 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04613518
Responsible party
Sponsor
First posted
Nov 3, 2020
Start date
Mar 15, 2021
Primary completion
May 31, 2023
Completion
Nov 29, 2023
Results posted
Jul 12, 2024
Last update
Jul 12, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion